|
National Security Staff Dual Use Research of Concern Sub-Interagency Policy Committee (NSS DURC Sub-PCC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
OD/OSP, NIAID
|
Develops policy options for US government oversight of dual-use research of concern (DURC).
|
|
National Survey of Family Growth
|
Health Survey
|
ACF, CDC
|
NICHD
|
The National Survey of Family Growth (NSFG) gathers information on family life, marriage and divorce, pregnancy, infertility, use of contraception, and men’s and women’s health. The survey results are used by the US Department of Health and Human Services and others to plan health services and health education programs and to do statistical studies of families, fertility, and health. The NSFG is used by: scholars in the behavioral sciences (e.g., sociology, demography, and economics) to study marriage, divorce, fertility, and family life; scholars in public health to study reproductive, maternal and infant health topics; agencies of the US Department of Health and Human Services to brief senior officials and to inform program decision-making; in research programs and in health and social service programs; state and local governments to plan health and social service programs; and the press, to prepare articles on a number of topics related to health and family life.
|
|
National Toxicology Program (NTP) Executive Committee
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, CDC, FDA
|
NIEHS, NCI
|
The National Toxicology Program (NTP) was established as a department-wide effort within the Public Health Service (PHS) on November 15, 1978. The program is comprised of the relevant PHS activities within the US Food and Drug Administration, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention, and the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health. The NIEHS Director serves as NTP Director and reports to the Assistant Secretary for Health. The NTP Executive Committee reviews progress on NTP activities directed toward carrying out its mission.
|
|
Native American Research Center for Health (NARCH)
|
Research Initiative
|
IHS
|
NIGMS, CSR, NCI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH
|
The Native American Research for Health (NARCH) program is a trans-NIH collaboration with the Indian Health Service (IHS) that supports collaborations between federally-recognized American Indian/Alaska Native (AI/AN) Tribes or Tribal organizations and research-intensive academic institutions that support health research projects prioritized by the Tribal communities. NARCH supports competitive research linked to the health priorities of AI/AN organizations and health disparities; increasing the capacity of both AI/AN organizations and research-intensive institutions to reduce distrust by AI/AN communities and people toward research; and developing a cadre of AI/AN scientists and health professionals engaged in biomedical, clinical, behavioral, and health services research who will be competitive in securing NIH funding.
|
|
Natural Compounds to Reduce Nitrate in Meat Products: Phytome
|
Research Initiative
|
CDC
|
NCI
|
NCI and the CDC are collaborating on a longitudinal human feeding study of processed meats and drinking water nitrate conducted by Maastricht University. CDC researchers are measuring volatile nitrosamines (NOCs) and nitrate concentrations in urine samples taken before and after consumption different types of processed meats with and without the intake of nitrate in drinking water. NCI will also evaluate nitrate and nitrosamine excretion levels in relation to the oral microbiome. Results from this study will characterize NOC formed from water nitrate and processed meat ingestion.
|
|
Natural Experiments and Effectiveness Studies in the Prevention and Control of Diabetes
|
Research Initiative
|
CDC
|
NIDDK
|
This project will focus on population-targeted interventions that health systems, communities, and governments can undertake to reduce the incidence of diabetes and its complications. This project will also strengthen the capacity of CDC and NIDDK to conduct vital health services and health policy research related to diabetes prevention and care.
|
|
NCI Clinical Trials and Translational Research Advisory Committee (CTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NCI
|
The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process. The Committee will provide advice on matters related to the conduct, oversight, and implementation of clinical trials and translational research across the Institute.
|
|
NCI National Cancer Informatics Program (NCIP) Nanotechnology Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NCI, NHLBI, NIBIB, NIEHS
|
The National Cancer Institute National Cancer Informatics Program (NCIP) Nanotechnology Working Group (NCIP Nano WG) was established in 2008 for researchers with a specific interest in informatics and computational approaches to nanotechnology, with a particular emphasis on nanomedicine. The goal of this Working Group is to demonstrate the scientific potential of federating nanotechnology databases through pilot projects aimed at integrated semantic search and retrieval of nanomedicine and nanotoxicology datasets that are applicable across nanoscience. The NCIP Nano WG comprises over 20 active participants from academia, government, and industry with diverse interests.
|
|
NCI/CCR-FDA Clinical Investigator Program
|
Research Initiative
|
FDA
|
NCI
|
Multilateral Benefit in a Joint Program to Recruit Combined FDA and NCI/CCR Clinical Investigators: the FDA gains an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field; NCI gains a clinical investigator and leader who understands regulatory considerations in drug development; and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind
|
|
NCI/FDA Memorandum of Understanding for Drug Related Information
|
Resource Development
|
FDA
|
NCI
|
The National Cancer Institute (NCI) Enterprise Vocabulary Services is working with the US Food and Drug Administration (FDA) to develop and support controlled terminology in several areas. More than 10,000 FDA terms and codes are stored in the NCI Thesaurus.
|